Abstract 11005: Clinical Value of Angiotensin-converting Enzyme Inhibitor and Angiotensin Receptor Blocker in the Patients of Coronary Artery Disease
In Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC), there was evidence of blood pressure-independent effects on the risk of major coronary disease event for angiotensin-converting enzyme inhibitors (ACEI), but not angiotensin receptor blocker (ARB). We investigated clinical outcomes of patients who treated with percutaneous coronary intervention (PCI) and administrated with ACEI or ARB.
Method: A total of 3943 patients (69.8±10.9 year-old, 77% male) who underwent PCI from April 2007 to July 2012 were enrolled. We evaluated 375 patients continuously treated with ACEI and 810 patients with ARB. The selection bias of medication was adjusted by propensity score-matching method; propensity score-matched ACEI (n=315) and ARB (n=315). We investigated major adverse cardiac-cerebral events (MACCE) and incidence of stent thrombosis (ST). MACCE were defined as all cause death, myocardial infarction (MI), target vessel revascularization (TVR) or cerebrovascular accidents (CVA).
Results: During median follow up period (512 days), all cause death, MI, TVR, CVA, MACCE, ST were not significant differences between 2 groups (ACEI vs. ARB; All cause death: 4.13% vs. 4.13%, p=1.0; MI: 0.95% vs. 0.32%, p=0.32; TVR: 12.4% vs. 17.8%, p=0.06; CVA: 1.90% vs. 1.59%, p=0.76; MACCE: 18.7% vs. 22.2%, p=0.28; ST: 1.90% vs. 0.63%, p=0.16).
Conclusion: There was no advantage using ACEI compared with ARB in the patients with coronary artery disease in this registry.
- © 2013 by American Heart Association, Inc.